Background: Superovulation in mice causes a delayed embryonic development in vitro and in vivo, an increased abnormal blastocyst formation, pronounced fetal growth retardation. Objective: Morphometric measurements the dimensions (thickness, length) of fetal kidney and suprarenal gland during the later intrauterine life, after superovulation induction. Methods: Twenty five mature female mice Swiss-Webster mice, these mice were divided into two groups: experimental (G1) (15animal/group) and control group(G2) (10 animal/group). Superovulation was induced by intraperitoneal (IP) injection of 7.5 IU of PMSG,then followed by 7.5 IU of HCG after 48 hours. Ovulation was taken place between 122± hours after injection of HCG. One mature male mice was placed with three superovulated female mice for mating. Pregnant females were sacrificed on gestational day eighteen in all experimental groups. For morphometric study 20 mice embryos were fixed in Bouin>s fixative, longitudinal sections of whole embedded embryo were stained by H&E, the specimens independently read. The dimensions (thickness, length) of fetal kidney and suprarenal gland were evaluated. Results: The statistical analysis showed significant decrease (P<0.01) in weights of fetuses in comparison with control group. The study was showed significant decrease (P< 0.01) in fetal kidney dimensions at day 18 of intrauterine life, when it compared to the fetal kidney of non superovulated group(control group). There was also significant decrease (P< 0.01) in the morphometric measurements of fetal suprarenal gland dimensions. Conclusion: The study improve that there is a delay in growth of kidney and suprarenal gland in fetal mice that belongs to mother undergo to superovulation induction before pregnancy.
Intrauterine insemination has an important role in the treatment of infertile couples. Usage of vaginal misoprostol therapy at the time of intrauterine insemination has been investigated, and its tolerability and effects on clinical pregnancy rates still questionable. To assess the effectiveness of vaginal misoprostol on some demographic characteristics and hormones level with a success rate of Intrauterine Insemination. the period of collection of patients extended from Sep. 2018 until May 2019. Eighty-one infertile couples who attended Al Nahrain University, High Institute for Diagnostic Infertility and Assisted Reproductive Technologies, and private fertility clinics were enrolled through this study. Divided into two groups, the next group received 100 µg vaginal misoprostol immediately after completion of the IUI procedure, while the control group was subjected to ordinary IUI procedure without adjunctive therapy. The mean of demographic data of body mass index, age, and duration of infertility was statistically insignificant in control, Misoprostol post-intrauterine insemination. The percentage of pregnancy rate in the control group 5.0% and it 19.5% in the Misoprostol post-intrauterine insemination group. Moreover, there are significant differences in pregnancy rates among all study groups. According to this study, there is no significant result of pregnancy occurrences correlated with, female age, male age, and body mass index, duration of infertility or type of infertility, hormone levels. Misoprostol use after intrauterine insemination has a positive impact on pregnancy outcome in the control group 5.0% and it 19.5% in Misoprostol post-intrauterine insemination group. Smaller doses (100 µg) of misoprostol can decrease side effects without affecting the outcome.